Cardinal Health report highlights cost savings and provider confidence in biosimilars

The 2026 Biosimilars Report released by Cardinal Health highlights the significant cost savings and growing provider confidence related to biosimilars within the U.S. healthcare system. Since their introduction in 2015, biosimilars have generated over $56 billion in savings, enhancing access to high-quality treatments and boosting overall value in healthcare.

The report, based on insights from 101 physician practices, reveals strong provider confidence, with nearly 99% of respondents feeling comfortable discussing biosimilars with patients. This reflects a robust clinical backing for these therapies. However, the report emphasizes that predictable reimbursement mechanisms are crucial for further adoption. A significant 68% of practices identified consistent reimbursement as "very important," while 59% preferred fixed discount models over fluctuating price reductions, which can create instability in reimbursement.

Oncology stands out as a leading field in biosimilar adoption, achieving an impressive average market share of 81% for newly launched products within five years. This rapid integration in oncology is anticipated to continue, with an expected 25 new FDA-approved biosimilars in various therapeutic areas—including immunology and retina—over the upcoming two years.

Key findings of the report underscore not just the strong confidence providers have in biosimilars, but also a potential "biosimilar void" if reimbursement stability is not maintained. Cardinal Health projects an opportunity to generate up to $181 billion in future savings under favorable market conditions and supportive policies.

In summary, Cardinal Health's report illustrates the transformative role biosimilars play in enhancing healthcare access, reducing costs, and fostering confidence among providers in their clinical applications.

Cardinal Health's latest Biosimilars Report underscores the transformative impact biosimilars are having on healthcare economics, particularly in oncology, where adoption rates are surging. The report reveals that since their introduction, biosimilars have contributed over $56 billion in savings to the U.S. healthcare system, affirming their role as cost-effective alternatives to traditional biologics. As projected, with an expected influx of nearly 25 new biosimilars gaining FDA approval in key therapeutic areas like oncology and immunology, the market stands on the cusp of an evolutionary phase that could amplify these savings even further.

From a market analysis perspective, this confidence from healthcare providers—99% report feeling assured in discussing biosimilars with patients—is a key indicator of potential growth for biosimilar products. This strong clinical validation translates to broader acceptance among patients and can drive volumes for companies operating in the biosimilar space.

However, the report identifies reimbursement stability as crucial for the sustainable adoption of biosimilars. With 68% of surveyed practices emphasizing the need for predictable reimbursement, stakeholders must advocate for policies that encourage consistent pricing models. The preference for set discount structures provides a pathway to sustained market growth and can mitigate the risks associated with incremental price changes.

For investors and market participants, focusing on companies that prioritize reimbursement stability and clear communication with providers could yield substantial returns. Furthermore, with the opportunity for an additional $181 billion in savings under optimal market conditions, there is considerable upside potential in biosimilar investments. In conclusion, monitoring policy developments and provider sentiment will be key for navigating this evolving landscape effectively.